Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

FDG PET/CT and MRI in Monitoring Very Early Therapy Response in Patients with Glioblastoma

Trial Status: administratively complete

This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) and magnetic resonance imaging (MRI) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT and MRI, may help measure a patient’s response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor’s glucose consumption which can be measured with imaging. FDG PET/CT and MRI shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.